Anti-CARD8 Antibody, clone 1C23 ZooMAb® Rabbit Monoclonal

Description

• General description: We are committed to bringing you greener alternative products, which adhere to one or more of the 12 Principles of Green Chemistry. This antibody is preservative-free, produced without the harm or sacrifice of animals and exceptionally stable to allow for ambient shipping and storage if needed, and thus aligns with "Waste Prevention", "Designing Safer Chemicals" and "Design for Energy Efficiency". Click here for more information.
• Specificity: Clone 1C23 is a ZooMAb® rabbit recombinant monoclonal antibody that detects CARD8. It targets an epitope within 25 amino acids from the C-terminal half.
• Immunogen: KLH-conjugated linear peptide corresponding to 25 amino acids from the of C-terminal half of human CARD8.
• Application: Quality Control TestingEvaluated by Western Blotting in Human umbilical vein endothelial cells (HUVEC) lysate.Western Blotting Analysis: A 1:10,000 dilution of this antibody detected CARD8 protein in Human umbilical vein endothelial cells (HUVEC) lysate.Tested Applications Western Blotting Analysis: A 1:1,000 dilution from a representative lot detected CARD8 in lysates from Jurkat cells and a 1:10,000 dilution detected CARD8 in lysates from SK-MEL-28 cells. Immunohistochemistry (Paraffin) Analysis: A 1:1,000 dilution from a representative lot detected CARD8 in human placenta tissue sections.Immunocytochemistry Analysis: A 1:100 dilution from a representative lot detected CARD8 in human umbilical vein endothelial cells (HUVEC).Affinity Binding Assay: A representative lot of this antibody bound CARD8 peptide with at least ten thousand-fold (10,000X) higher than with non-specific control peptide.Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user.
• Target description: Caspase recruitment domain-containing protein 8 (UniProt: Q9Y2G2-5; EC:3.4.-.-; also known as CARD-inhibitor of NF-kappa-B-activating ligand (CARDINAL), Tumor up-regulated CARD-containing antagonist of CASP9 (TUCAN), CARD8-CT, CARD8-NT) is encoded by the CARD8 (also known as DACAR, KIAA0955, NDPP1) gene (Gene ID: 22900) in human. CARD8 is characterized by the presence of a CARD domain, which is crucial for protein-protein interactions, particularly in the formation of inflammasomes and signaling complexes. The protein also contains a FIIND (function to find domain) and a NOD (nucleotide-binding oligomerization domain), which are involved in self-cleavage and oligomerization, respectively. CARD8 primarily functions in the regulation of inflammatory responses and apoptosis. It acts as an inhibitor of NF- B, a key transcription factor in inflammatory processes, and plays a role in the formation of inflammasomes, which are essential for the activation of inflammatory caspases and the processing of pro-inflammatory cytokines like IL-1β. The expression of CARD8 is widespread but varies significantly among different tissues. It is predominantly found in immune cells and tissues with high metabolic activity, which are often sites of inflammation. Expression levels can be influenced by inflammatory stimuli and are subject to regulation by various cytokines and pathogen-associated molecular patterns. Dysregulation of CARD8 expression or function has been linked to conditions such as rheumatoid arthritis, Crohn′s disease, and gout, where aberrant inflammasome activity leads to excessive inflammation. Additionally, mutations or alterations in the CARD8 gene have been associated with increased susceptibility to these diseases. This ZooMAb® recombinant monoclonal antibody, generated by our proprietary technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals.
• Physical form: Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS with 5% Trehalose, normal appearance a coarse or translucent resin. The PBS/trehalose components in the ZooMAb formulation can have the appearance of a semi-solid (bead like gel) after lyophilization. This is a normal phenomenon. Please follow the recommended reconstitution procedure in the data sheet to dissolve the semi-solid, bead-like, gel-appearing material. The resulting antibody solution is completely stable and functional as proven by full functional testing. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 µL.
• Reconstitution: 300 µg/mL after reconstitution at 25 µL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.
• Storage and Stability: Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 µL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.
• Legal Information: ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany
• Disclaimer: Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.